




DIFFERENTIAL PRIVACY APPROACHES IN A CLINICAL TRIAL





MARTIN LEUCKERT

OTTO-VON-GUERICKE UNIVERSITY MAGDEBURG

INTRODUCTION



INTRODUCTION



Private data

Sensitive data

PROBLEM STATEMENT

EUROPEAN REGULATIONS:




- GENERAL PROTECTION REGULATION (GDPR)
- RL 93/42/EWG (MEDDEV)
- GCP DIRECTIVE (DIRECTIVE 2005/28/EC)
- CLINICAL TRIAL DIRECTIVE' (DIRECTIVE 2001/20/EC)

NATIONAL REGULATIONS

- MEDIZINPRODUKTEGESETZ (MPG)
 - 90/385/EWG
 - 90/42/EWG
 - 98/79/EG

PROBLEM STATEMENT

SO WHAT EXACTLY IS THE PROBLEM?




- Specialists
- Scientists

HOSPITALS ANONYMIZE OR RATHER PSEUDONYMIZE THE DATA
BUT IS SUBJECT STILL AT RISK? YES.

INTRODUCTION & PROBLEM STATEMENT

NETFLIX PRIZE 2006





Many Netflix users rated the same movies similarly at IMDB.

„Robust De-anonymization of Large Sparse Datasets“ by Arvind Narayanan and Vitaly Shmatikov, University of Texas at Austin, 2008

PROBLEM STATEMENT

SO WHAT EXACTLY IS THE PROBLEM?





- Specialists
- Scientists



INVOLVED THIRD PARTIES FOR DATA ANALYSIS
MUST BE CONSIDERED MALICIOUS

INTRODUCTION & PROBLEM STATEMENT


PURE CRYPTO SOLUTIONS EXIST



**FULLY HOMOMORPHIC ENCRYPTION
GARBLED CIRCUITS, SECRET SHARING
CAN BE EFFICIENT FOR SOME SPECIFIC CASES**

INTRODUCTION & PROBLEM STATEMENT

DIFFERENTIAL PRIVACY



INTRODUCTION & PROBLEM STATEMENT

DIFFERENTIAL PRIVACY

„The Algorithmic Foundations of Differential Privacy“ by Cynthia Dwork, Microsoft Research & Aaron Roth, University of Pennsylvania, 2014.

“Differential privacy” describes a promise, made by a data holder, or curator, to a data subject: “You will not be affected, adversely or otherwise, by allowing your data to be used in any study or analysis, no matter what other studies, data sets, or information sources, are available.”

“Data cannot be Fully Anonymized and Remain Useful.”



Can I call my algorithm \mathcal{M} ε -DP?

$$L^\xi = \ln \left(\frac{\Pr[\mathcal{M}(x) = \xi]}{\Pr[\mathcal{M}(y) = \xi]} \right)$$

\mathcal{M} is called ε -DP, if and only if $|L^\xi| \leq \varepsilon$


BACKGROUND & SIGNIFICANCE

EXAMPLE 1: “EFFICIENT PRIVACY-PRESERVING CLASSIFICATION OF ECG SIGNALS”, BARNI ET AL., 2009




BACKGROUND & SIGNIFICANCE

EXAMPLE 2 - DIFFERENTIAL PRIVACY: “PROTECTING LOCATIONS WITH DIFFERENTIAL PRIVACY UNDER TEMPORAL CORRELATIONS”, YONGHUI, LI, EMORY UNIVERSITY AT ATLANTA, 2015.



BACKGROUND & SIGNIFICANCE


EXAMPLE 3 - HARDWARE SOLUTION: “AN ALGORITHMIC FRAMEWORK FOR DIFFERENTIALLY PRIVATE DATA ANALYSIS ON TRUSTED PROCESSORS”, ALLEN, OHRIMENKO ET AL.



RESEARCH DESIGN & METHODS


SMART PREVENT DIABETIC FEET: 300 SUBJECTS (150 USING DEVICE)

ALL




Classic onsite screening every six months

STUDY GROUP




Ambulant



Data inspection


Combining results for a more sophisticated treatment of the subjects



RESEARCH DESIGN & METHODS

COMPARE TWO BASIC MECHANISMS FOR NUMERIC INPUT PERTURBATION

- LAPLACIAN MECHANISM
- FUNCTIONAL MECHANISM



RESEARCH DESIGN & METHODS

EXPERIMENTAL SETUP

HARDWARE & ENVIRONMENT


- INTEL CORE I7-8665U
- 48GB RAM
- MS ML.NET

$$MSE = \frac{1}{N} \sum_{i=1}^N (y_i - y_i^*)^2$$

DATA

- 10-FOLD CROSS-VALIDATION
- 200K DATA RECORDS

OVERVIEW



CONCLUSION

WE EXPLORED DIFFERENTIAL PRIVATE MACHINE LEARNING

PERFORMANCE

SIGNIFICANTLY FASTER
THAN PURELY
CRYPTOGRAPHIC
SOLUTIONS

USABILITY

INCREASES WITH HIGHER
 ϵ

STRONGLY INFLUENCED
BY CHOSEN MECHANISM

SECURITY GUARANTEES

DECREASE WITH
HIGHER ϵ

STRONGLY INFLUENCED
BY CHOSEN MECHANISM

CONCLUSION

DIFFERENTIAL PRIVACY CAN BE APPLIED TO CLINICAL TRIALS

BUT SOPHISTICATED DECISIONS REQUIRED ABOUT MECHANISM, PERTURBATION, ϵ , USABILITY

Differential Privacy can provide security and privacy, if applied correctly.

Out-of-the-box solutions required for smaller scale clinical trials.

Thank you.